This clinical trial is focused on studying the effects of a medication called dapagliflozin on patients who have received a kidney transplant and are experiencing chronic kidney disease. Chronic kidney disease is a condition where the kidneys gradually lose their ability to filter waste from the blood effectively. The medication being tested, dapagliflozin, is taken in the form of a 10 mg film-coated tablet known as Forxiga. The purpose of the study is to observe how this medication might help protect the kidneys, a concept known as nephroprotection, by reducing the amount of protein in the urine, which is a sign of kidney damage.

Participants in the study will take dapagliflozin and be monitored over a period of six months. The study will look at how well the medication works in reducing protein levels in the urine and whether it helps maintain kidney function. The study will also observe any changes in blood pressure, weight, and blood sugar levels, as well as any side effects that may occur, such as infections or changes in blood chemistry. The goal is to see if dapagliflozin can provide a protective effect on the kidneys in patients who have undergone a kidney transplant.

Throughout the study, researchers will also examine how dapagliflozin interacts with other medications that patients may be taking to suppress their immune system, which is necessary after a kidney transplant to prevent the body from rejecting the new organ. The study will help determine if dapagliflozin is a safe and effective option for protecting kidney function in these patients. Participants will be closely monitored for any adverse reactions or complications during the study period.